Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Rhythm Pharmaceuticals, Inc. (RYTM : NSDQ)
 
 • Company Description   
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Number of Employees: 414

 
 • Price / Volume Information   
Yesterday's Closing Price: $102.10 Daily Weekly Monthly
20 Day Moving Average: 740,389 shares
Shares Outstanding: 68.53 (millions)
Market Capitalization: $6,997.22 (millions)
Beta: 1.88
52 Week High: $122.20
52 Week Low: $74.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.69% -6.38%
12 Week 25.49% 22.06%
Year To Date -4.62% -11.38%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
222 BERKELEY STREET 12TH FLOOR
-
BOSTON,MA 02116
USA		 ph: 857-264-4280
fax: 857-264-4299		 dconnolly@rhythmtx.com http://www.rhythmtx.com
 
 • General Corporate Information   
Officers
David P. Meeker - Chief Executive Officer; Chairman and Director
Hunter Smith - Chief Financial Officer
Stuart Arbuckle - Director
Jennifer L. Good - Director
Christophe R. Jean - Director

Peer Information
Rhythm Pharmaceuticals, Inc. (CORR.)
Rhythm Pharmaceuticals, Inc. (RSPI)
Rhythm Pharmaceuticals, Inc. (CGXP)
Rhythm Pharmaceuticals, Inc. (BGEN)
Rhythm Pharmaceuticals, Inc. (GTBP)
Rhythm Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 76243J105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/04/26
Share - Related Items
Shares Outstanding: 68.53
Most Recent Split Date: (:1)
Beta: 1.88
Market Capitalization: $6,997.22 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.74 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.10 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 44.58% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 56.93
Price/Cash Flow: -
Price / Sales: 32.22
EPS Growth
vs. Year Ago Period: -2.47%
vs. Previous Quarter: -13.70%
Sales Growth
vs. Year Ago Period: 83.81%
vs. Previous Quarter: 4.99%
ROE
06/30/26 - -
03/31/26 - -203.25
12/31/25 - -266.56
ROA
06/30/26 - -
03/31/26 - -44.99
12/31/25 - -45.01
Current Ratio
06/30/26 - -
03/31/26 - 4.17
12/31/25 - 4.41
Quick Ratio
06/30/26 - -
03/31/26 - 3.89
12/31/25 - 4.16
Operating Margin
06/30/26 - -
03/31/26 - -93.33
12/31/25 - -103.57
Net Margin
06/30/26 - -
03/31/26 - -93.33
12/31/25 - -103.57
Pre-Tax Margin
06/30/26 - -
03/31/26 - -92.89
12/31/25 - -103.31
Book Value
06/30/26 - -
03/31/26 - 1.79
12/31/25 - 2.08
Inventory Turnover
06/30/26 - -
03/31/26 - 0.96
12/31/25 - 0.91
Debt-to-Equity
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
Debt-to-Capital
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
 

Powered by Zacks Investment Research ©